Novel statins: pharmacological and clinical results.
Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
Bolego
Chiara
C
Nutrition Foundation of Italy, Via S Pietro all'Orto 17, 20121 Milan, Italy.
Poli
Andrea
A
Cignarella
Andrea
A
Catapano
Alberico L
AL
Paoletti
Rodolfo
R
D000818:Animals; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D005464:Fluorobenzenes / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D009281:Naphthalenes / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides
D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C430123:LFA703; D009281:Naphthalenes; D011743:Pyrimidines; D011804:Quinolines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; C108475:pitavastatin